🇪🇺 Palsonify in European Union

EMA authorised Palsonify on 23 April 2026

Marketing authorisation

EMA — authorised 23 April 2026

  • Application: EMEA/H/C/006636
  • Marketing authorisation holder: Crinetics Pharmaceuticals Europe GmbH
  • Local brand name: Palsonify
  • Indication: Palsonify is indicated for the medical treatment of adult patients with acromegaly.
  • Pathway: orphan
  • Status: approved

The EMA has approved Palsonify, a medicinal product developed by Crinetics Pharmaceuticals Europe GmbH, for the treatment of adult patients with acromegaly. This approval was granted under the orphan designation, which is reserved for medicines treating rare diseases. Palsonify is the local brand name for this treatment in the European Union.

Read official source →

Palsonify in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Metabolic approved in European Union

Frequently asked questions

Is Palsonify approved in European Union?

Yes. EMA authorised it on 23 April 2026.

Who is the marketing authorisation holder for Palsonify in European Union?

Crinetics Pharmaceuticals Europe GmbH holds the EU marketing authorisation.